Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) Lemzoparlimab With or Without Oral/IV Dexamethasone and in Combination With Oral/IV/Subcutaneous Anti-Myeloma Regimens in Adult Participants With Multiple Myeloma

NCT04895410 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

8

Enrollment

INDUSTRY

Sponsor class

Stopped Strategic considerations

Conditions

Multiple Myeloma

Interventions

BIOLOGICAL: Lemzoparlimab
DRUG: Dexamethasone
DRUG: Carfilzomib
DRUG: Pomalidomide
BIOLOGICAL: Daratumumab

Sponsor

AbbVie